Nothing said here yet.
to join the conversation.
| Charney Laurence NDirector | Sell | 5,000 | $274.8K | Thu, Sep 10 |
One concrete shift for TG Therapeutics this year was the push to simplify and broaden BRIUMVI use, from single 600 mg Day 1 infusions in relapsing multiple sclerosis to new trials in conditions like myasthenia gravis and treatment-resistant schizophrenia.
Investors are now focused on the company’s projected third-quarter 2026 results, estimated for Monday, November 2.
TG Therapeutics (TGTX) has become a focal point after releasing early Phase 1 data on azercabtagene zapreleucel in progressive multiple sclerosis, giving investors fresh clinical information to weigh against the current valuation.
TG Therapeutics has turned into one of the more eye catching biotech stories on Nasdaq in recent years, and the share price move now raises a simple question for you as an investor: Is the current valuation of TG Therapeutics still grounded in what the…
TG Therapeutics reported early Phase 1 data for azer-cel in progressive multiple sclerosis and presented extensive long term and real world BRIUMVI findings at MSToronto2026.
TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Phase 1 trial evaluated patients whose disabilities continued to worsen despite receiving other treatments.
TG Therapeutics shares climb 59.9% in six months on strong Briumvi sales uptake, higher 2026 revenue guidance and studies targeting additional indications.
TG Therapeutics, Inc. has scheduled multiple data presentations at the 10th Joint ACTRIMS-ECTRIMS Meeting (MSToronto2026), including a late-breaking oral session on initial Phase 1 results for azer-cel, an allogeneic CD19-directed CAR T-cell therapy in…